Product Reports Resources Pricing Login Book a demo

Vernal Biosciences

Biotech & Life Sciences · Colchester, United States · Founded 2021

Manufacturer of high purity mRNA for research and clinical use MoreLess

Vernal Biosciences is a Contract Development and Manufacturing Organization (CDMO) specializing in the production of high-quality mRNA (messenger RNA) for use in advanced therapeutics. The company's primary market is the biotech and pharmaceutical industry, specifically organizations that require mRNA for research and development (R&D) and clinical trials.

Vernal Biosciences operates on a transactional business model, providing on-demand, high-purity mRNA and LNP-mRNA (Lipid Nanoparticle mRNA) supplies and services. This model allows clients to avoid the cost and risk of building their own teams and facilities for mRNA production. Instead, they can focus on other high-value operations such as drug discovery, clinical development, and marketing.

The company's platform and analytical methods aim to eliminate the guesswork and lengthy development cycles often associated with manufacturing processes in the advanced therapeutics field. Vernal Biosciences ensures consistent quality across all scales of mRNA and LNP-mRNA production, providing a de-risked, advanced staging ground for research and clinical supply.

In addition to mRNA production, Vernal Biosciences also offers associated services such as process development and quality control methods. The company's quality-by-design driven platform technologies cover the entire value chain of mRNA medicines, accommodating all mRNA needs.

In summary, Vernal Biosciences is a key player in the mRNA production sector, providing high-quality mRNA and associated services to biotech and pharmaceutical companies.

Keywords: mRNA Production, Pharmaceutical Industry, Biotech Industry, Contract Development and Manufacturing Organization (CDMO), Quality Control, Process Development, Transactional Business Model, Advanced Therapeutics, Clinical Trials, Research and Development (R&D).

Company overview

Vernal Biosciences company information

The essential company record, classifications and operating signals in one place.

Status
Operational
Founded
2021
Headquarters
Colchester, United States
Employees
7
Open positions
None listed
Dealroom signal
60.3
client focusb2bsub industryPharmaceuticalsub industryBioTechnologybusiness modelManufacturingindustryHealthsectorBiotechnologysectorVaccinessectorGenetics and genomicssectorBiotech and PharmasectormRNA MedicinessectorHard TechsectorDT and LSsectorscience-based

Valuation & funding

Vernal Biosciences funding history

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
EARLY VCEquity / VC Jun 2023 $20M $105M Vermont Center for Emerging Technologies · Ampersand Capital Partners · Dynamk Capital · Charles River Laboratories International
EARLY VCEquity / VC Jun 2022 $21M $84M Alloy Therapeutics · Dynamk Capital · Charles River Laboratories International · ATUM
SEEDEquity / VC Jul 2021 Vermont Center for Emerging Technologies · Alloy Therapeutics
Showing 3 recorded eventsUnlock the complete deal history →

Financials

Workforce over time

Available workforce history. Financial fields without reported data are omitted.

YearEmployees
2026 7
2025 17
2024 46
2023 61
2022 49
Company filings, research estimates and Dealroom dataOpen the full financial model →

Growth signals

Vernal Biosciences website traffic

Latest recorded traffic for Vernal Biosciences is 2.1K monthly website visits, down 12.5% over the last three months. Vernal Biosciences's team declined 58.8% over the past year.

Latest monthly visits2.1K 3-month web change-12.5% 1-year team growth-58.8%
Monthly website visits46 observations · Oct 2022–Jul 2026
Hover or focus a point to see its exact monthly valueCompare with peers →

Comparisons

Vernal Biosciences compared with similar companies

Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.

Showing 8 of the closest matchesCompare every metric →

Talent graph

Vernal Biosciences's talent

Book a demo to see the people
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

7 investors on Vernal Biosciences's cap table

Sourced from Dealroom's funding and investor records.

Seed 2 investors entered at this stage
Vermont Center for Emerging Technologies
Alloy Therapeutics
Series A 4 investors entered at this stage
Dynamk Capital
Ampersand Capital Partners
Charles River Laboratories International
ATUM
Other known 1 additional known investor
VCET Capital

Global footprint

Where Vernal Biosciences has talent and traffic

Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

In the news

Latest news about Vernal Biosciences

Recent press, funding announcements, and product moves mentioning Vernal Biosciences — open to read from the original sources.

See all news

Market sentiment

What the market is saying about Vernal Biosciences

An AI-synthesized read of the highest-engagement posts about Vernal Biosciences on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Vernal Biosciences’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.